Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat

Peritoneal Dialysis International

Volumn 24, Issue 2, 2004, Pages 115-122

  Park, Sun Hee ^a   Lee, Eun Gyui ^b   Kim, In San ^b   Kim, Yong Jin ^c   Cho, Dong Kyu ^a   Kim, Yong Lim ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Yeungnam University College of Medicine   (South Korea)

Author keywords

Glucose degradation products; Peritoneal transport; Vascular endothelial growth factor; Vascularization

Indexed keywords

CEFTAZIDIME; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; MONOCLONAL ANTIBODY; PERITONEAL DIALYSIS FLUID; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIALYSIS MEMBRANE; EQUILIBRIUM DIALYSIS; GLUCOSE TRANSPORT; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MALE; MEMBRANE PERMEABILITY; MESOTHELIUM; NONHUMAN; OMENTUM; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; RAT; REVIEW; TISSUE DISTRIBUTION; VASCULARIZATION;

EID: 1942454229     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080402400202     Document Type: Review

References (21)

1. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9:41-5.
2. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000; 20(Suppl 4):S22-42.
3. Krediet RT, Van Esch S, Smit W, Michels WM, Zweers MM, Ho-Dac-Pannekeet MM, et al. Peritoneal membrane failure in peritoneal dialysis patients. Blood Purif 2002; 20:489-93.
4. Witowski J, Bender TO, Gahl GM, Frei U, Jorres A. Glucose degradation products and peritoneal membrane function. Perit Dial Int 2001; 21:201-5.
5. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
6. Millar DJ, Holmes C, Faict D, Dawnay A. Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation. Adv Perit Dial 1998; 14:191-4.
7. Dawnay AB, Millar DJ. Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int 1997; 17:52-8.
8. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463: 260-4.
9. Moore HL. A chronic catheter model for PD exchanges in the ambulatory rat [Abstract]. Perit Dial Int 1992; 12(Suppl 1):S141.
10. Waniewski J, Heimburger O, Werynski A, Lindholm B. Aqueous solute concentration and evaluation of mass transport coefficient in peritoneal dialysis. Nephrol Dial Transplant 1992; 7:50-6.
11. Zweers MM, Struijk DG, Smit W, Krediet RT. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med 2001; 137: 125-32.
12. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118:445-50.
13. Lal BK, Varma S, Pappas PJ, Hobson RW 2nd, Duran WN. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res 2001; 62:252-62.
14. Kim BS, Chen J, Weinstein T, Noiri E, Goligorsky MS. VEGF expression in hypoxia and hyperglycemia: reciprocal effect on branching angiogenesis in epithelial-endothelial co-cultures. J Am Soc Nephrol 2002; 13: 2027-36.
15. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med 1999; 134:124-32.
16. De Vriese AS, Tilton RG, Stephan CC, Lameire NH. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12:1734-41.
17. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
18. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12:2029-39.
19. Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int 2001; 21(Suppl 3):S368-72.
20. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solution on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22:171-7.
21. Kang DH, Hong YS, Lim HJ, Choi JH, Han DS, Yoon KI. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta 1 of human peritoneal mesothelial cells: effect of cytokine costimulation. Perit Dial Int 1999; 19:221-30.